

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



上海復旦張江生物醫藥股份有限公司

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code:1349)

SUPPLEMENTAL ANNOUNCEMENT ESTIMATED RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2022

This announcement is made by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.* (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the announcement dated 15 August 2022 (the “**Announcement**”) of the Company. Unless otherwise stated, terms used in this announcement shall have the same meaning as those defined in the Announcement.

In order to avoid potentially misleading statement, the Company would like to further announce that (i) the original disclosure that “it is expected to record an unaudited net profit attributable to shareholders of the Company of approximately RMB-40 million to RMB-30 million during the Reporting Period” in the Announcement shall be clarified as “it is expected to record an unaudited net loss attributable to shareholders of the Company of approximately RMB30 million to RMB40 million during the Reporting Period”; and (ii) the original disclosure that “The unaudited net profit attributable to shareholders of the Company after deducting the non-recurring profit or loss is expected to be approximately RMB-50 million to RMB-40 million” in the Announcement shall be clarified as “The unaudited net loss attributable to shareholders of the Company after deducting the non-recurring profit or loss is expected to be approximately RMB40 million to RMB50 million”. Save as disclosed above, all of the other information and contents set out in the Announcement remain unchanged. This announcement is supplemental to and should be read in conjunction with the Announcement.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board

Wang Hai Bo

Chairman

As at the date on the publication of this announcement, the Board comprises:

Mr. Wang Hai Bo (Executive Director)

Mr. Su Yong (Executive Director)

Mr. Zhao Da Jun (Executive Director)

Mr. Shen Bo (Non-executive Director)

Ms. Yu Xiao Yang (Non-executive Director)

Mr. Zhou Zhong Hui (Independent Non-executive Director)

Mr. Lam Yiu Kin (Independent Non-executive Director)

Mr. Xu Qing (Independent Non-executive Director)

Mr. Yang Chun Bao (Independent Non-executive Director)

Shanghai, the PRC

24 August 2022

** For identification purpose only*